NEPHROS INC - Common Stock - $0.001 par value (NEPH)
CUSIP: 640671400
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Common Stock - $0.001 par value
- Shares outstanding
- 10,630,964
- Total 13F shares
- 632,473
- Share change
- -10,698
- Total reported value
- $968,000
- Price per share
- $1.53
- Number of holders
- 15
- Value change
- -$108,653
- Number of buys
- 9
- Number of sells
- 6
Quarterly Holders Quick Answers
What is CUSIP 640671400?
CUSIP 640671400 identifies NEPH - NEPHROS INC - Common Stock - $0.001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 640671400:
Top shareholders of NEPH - NEPHROS INC - Common Stock - $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| WEXFORD CAPITAL LP |
13F
|
Company |
34%
|
3,663,969
|
$533,734,000 | — | 31 Mar 2022 | |
| BARD ASSOCIATES INC |
13F
|
Company |
2.3%
|
246,408
|
$1,084,000 | — | 31 Mar 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.2%
|
122,978
|
$541,000 | — | 31 Mar 2022 | |
| Cowen Prime Advisors LLC |
13F
|
Company |
0.76%
|
80,400
|
$354,000 | — | 31 Mar 2022 | |
| Daron Evans |
3/4/5
|
CEO Specialty Renal Products |
—
mixed-class rows
|
179,718
mixed-class rows
|
$351,795 | — | 24 May 2021 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.52%
|
55,710
|
$245,000 | — | 31 Mar 2022 | |
| Andrew Astor Power |
3/4/5
|
President, CEO & CFO, Director |
—
mixed-class rows
|
131,385
mixed-class rows
|
$204,342 | — | 05 Mar 2022 | |
| BLAIR WILLIAM & CO/IL |
13F
|
Company |
0.34%
|
36,249
|
$159,000 | — | 31 Mar 2022 | |
| ELKHORN PARTNERS LIMITED PARTNERSHIP |
13F
|
Company |
0.22%
|
23,712
|
$104,000 | — | 31 Mar 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.19%
|
20,317
|
$89,000 | — | 31 Mar 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.17%
|
17,750
|
$78,000 | — | 31 Mar 2022 | |
| Wesley S. Lobo |
3/4/5
|
Chief Marketing Officer |
—
mixed-class rows
|
206,714
mixed-class rows
|
$77,461 | — | 16 Feb 2022 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
0.12%
|
12,813
|
$56,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
10,192
|
$44,000 | — | 31 Mar 2022 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.08%
|
8,669
|
$38,000 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.07%
|
7,525
|
$33,000 | — | 31 Mar 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
448
|
$2,000 | — | 31 Mar 2022 |
Institutional Holders of NEPHROS INC - Common Stock - $0.001 par value (NEPH) as of Q2 2022
As of 30 Jun 2022,
NEPHROS INC - Common Stock - $0.001 par value (NEPH) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
632,473 shares.
The largest 10 holders included
BARD ASSOCIATES INC, VANGUARD GROUP INC, HighTower Advisors, LLC, Cowen Prime Advisors LLC, BLAIR WILLIAM & CO/IL, ELKHORN PARTNERS LIMITED PARTNERSHIP, MORGAN STANLEY, STATE STREET CORP, CITADEL ADVISORS LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
15
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
13
Q2 2022 holders
15
Holder diff
2
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.